Most patients with advanced NSCLC with EGFR activating mutations will develop resistance after 6–9 months of treatment with first-generation reversible TKIs such as erlotinib, gefitinib, (5, 16, 20). Here, EGFR is linked to non-small cell lung carcinoma.